<DOC>
	<DOCNO>NCT01745913</DOCNO>
	<brief_summary>The purpose study compare efficacy haplo-cord transplant ( investigational arm ) commonly used procedure cell contain one two umbilical cord infuse ( standard arm ) . We hypothesize reduced intensity condition haplo-cord transplant result fast engraftment neutrophil platelet , low incidence acute chronic graft versus host disease , low frequency delay opportunistic infection , reduce transfusion requirement , shorten length hospital stay promise long term outcome . We also hypothesize umbilical cord blood selection prioritize match good match donor identify rapidly subject .</brief_summary>
	<brief_title>Randomized HaploCord Blood Transplantation v . Double Umbilical Cord Blood Transplantation Hematologic Malignancies</brief_title>
	<detailed_description>This clinical trial subject hematologic malignancy ( acute myelogenous leukemia , acute lymphocytic leukemia , Hodgkin 's Non-Hodgkin 's lymphoma , myelodysplastic syndrome ) need donor stem cell transplant , umbilical cord blood transplant think best option . For allogeneic transplant donor , typically try use related family member , brother sister , volunteer donor 'HLA match ' , i.e . share similar protein cell . This study subject match sibling donor match unrelated donor available . This study test new method bone marrow transplantation call combine haplo-identical cord ( haplo-cord ) transplantation . In procedure , cell relate donor share half HLA protein ( haplo-identical ) collect blood , well cell umbilical cord , transplant . It hop use cell haplo-identical relative , subject faster recovery require few transfusion . Over time haplo-identical cell relative replace cell cord blood . The combined transplantation haplo-identical stem cell cord blood previously use approximately 60 subject encouraging result . The purpose study compare efficacy haplo-cord transplant ( `` investigational '' arm ) commonly used procedure cell contain one two umbilical cord infuse ( `` standard '' arm ) . Subjects randomly assign either haplo-cord group umbilical cord group . If randomize haplo-cord group , family member undergo stem cell collection . In arm , subject receive `` condition regimen '' prior transplantation . The condition regimen consist chemotherapy , meant destroy cancer cell suppress immune system allow transplanted cell grow . Subjects remain hospital stem cell fully recover , usually 4 6 week transplant . Subjects bone marrow aspiration biopsy 3 week , 4 week , 2 month , 6 month 1 year transplant yearly thereafter . Participation study continue 5 year transplantation .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Subject must histologically cytologically confirm diagnosis : Acute Myelogenous Leukemia Myelodysplastic Syndrome Acute Lymphocytic Leukemia Lymphoma ( Hodgkin 's Lymphoma NonHodgkin 's Lymphoma ) 2 . Must &gt; 18 year age 3 . Subject likely benefit allogeneic transplant opinion transplant physician 4 . An human leukocyte antigen ( HLA ) identical relate unrelated donor identify within appropriate time frame 5 . Karnofsky Performance Status ( KPS ) &gt; 80 6 . Subject acceptable organ marrow function define : Serum bilirubin &lt; 2.0mg/dL ALT ( SGPT ) 3 X upper limit normal Creatinine Clearance &gt; 50 mL/min estimate modify MDRD equation.18 7 . Ability understand willingness sign write informed consent document . 8 . A preliminary search identify : 1 . Appropriate umbilical cord single , necessary double umbilical cord blood ( UCB ) transplant AND 2 . An appropriate single UCB well appropriate haplo donor haplocord transplant 1 . Myeloproliferative disorder , hemoglobinopathy , severe aplastic anemia diagnosis list 3.1.1 2 . Life expectancy severely limited concomitant illness uncontrolled infection 3 . Subjects severely decrease Left Ventricular Ejection Fraction ( LVEF ) impair pulmonary function test ( PFTs ) 4 . Subject evidence chronic active hepatitis cirrhosis 5 . Subject HIVpositive 6 . Subject pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
</DOC>